Rockwell Medical (RMTI) Announces Triferic™ Iron Replacement Clinical Data Selected For Three Abstract Presentations At National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 In Las Vegas, NV
4/14/2014 9:16:42 AM
WIXOM, Mich., April 14, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Triferic™ have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Triferic™ is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by